HuMAB companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (462)	12/11/2002 10:59:36 AM
From: Icebrg	Read Replies (1) of 1022

Thanks Nigel! It seems as if Viventia has the ambition to develop something similar to what ImmunoGen is working on. The good question to ask might be why the have chosen to use humanization rather than fully human antibodies (from ABGX or MEDX for example). I always though that humanization as a technology was disappearing. Perhaps they already have a mouse antibody that just needs some fixing. It may also be noted that Biovation seems to be the company that has provided the technology for Millennium's anti-PSMA agents MLN591RL and MLN2704 aka MLN591-DM1. From MLNM's new website: MLN591, the antibody component of MLN2704 (and MLN591RL), is the first monoclonal antibody engineered using a technique known as DeImmunisation™, which may allow for repeat dosing. Antibodies humanized using current approaches can induce T-cell responses, triggering immunogenicity. DeImmunisation removes a pivotal trigger for immunogenicity. To date, immune responses to MLN591 have not been reported in human subjects who have received the antibody. This was of course not Millennium's choice (I guess) but something that was taken over when the mAb was licensed from BZL. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next